Financials data is unavailable for this security.
View more
Year on year Henan Lingrui Pharmaceutical Co Ltd grew revenues 10.31% from 3.00bn to 3.31bn while net income improved 22.09% from 465.33m to 568.11m.
| Gross margin | 72.35% |
|---|---|
| Net profit margin | 18.96% |
| Operating margin | 21.88% |
| Return on assets | 14.20% |
|---|---|
| Return on equity | 24.11% |
| Return on investment | 23.52% |
More ▼
Cash flow in CNYView more
In 2023, Henan Lingrui Pharmaceutical Co Ltd increased its cash reserves by 26.37%, or 310.99m. The company earned 813.43m from its operations for a Cash Flow Margin of 24.56%. In addition the company used 229.70m on investing activities and also paid 272.73m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 5.10 |
|---|---|
| Tangible book value per share | 4.71 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.18 |
|---|---|
| Quick ratio | 0.9579 |
| Total debt/total equity | 0.0074 |
|---|---|
| Total debt/total capital | 0.0073 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 33.33% and 19.98%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 4.04% |
|---|---|
| Div growth rate (5 year) | 39.77% |
| Payout ratio (TTM) | 66.76% |
| EPS growth(5 years) | 19.31 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 27.89 |
More ▼
